Citations

Clear

13603 citation(s) found for "_, _".

PCO25-209: Inhibition of Aurora A Kinase Restores Sensitivity to CDK 4/6 Inhibition of ER Positive Breast Cancers in Acquired Resistance PDX Model
Gil, Małgorzata , Alderson, Meera, D’Assoro, Antonio B., Li, Shunqiang , Yu, Tao , Alderson, Meera, Takabe, Kazuaki , Opyrchal, Mateusz

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 28, 2025 | Volume: 23 | Issue: 3.5 | Pages: No page available

10.6004/jnccn.2024.7309 Get It

HSR25-185: A Multicenter Retrospective Study of Treatment and Survival Outcomes of Patients With Secondary CNS Relapsed DLBCL in the Modern Era
Okcu, Izel, Nowakowski, Grzegorz S. , Amengual, Jennifer E. , Ross, Che, Bock, A., Okcu, Izel , Pierce, Andrew L., Tolu, Seda , Graber, Jerome J. , Hu, Boyu , Ermann, Daniel A.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 28, 2025 | Volume: 23 | Issue: 3.5 | Pages: No page available

10.6004/jnccn.2024.7347 Get It

CRE25-036: Breast Implant Associated Squamous Cell Carcinoma (BIA-SCC): A Mayo Clinic Multidisciplinary Approach to Treatment
Prasad, Dhauna Karam, Corbin, Kimberly S. , Solanki, Malvika , Block, M.S., O’Sullivan, Ciara C. , Hieken, Tina J. , Mardini, Samir , Markovic, Svetomir N.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 28, 2025 | Volume: 23 | Issue: 3.5 | Pages: No page available

10.6004/jnccn.2024.7109 Get It

QIM25-237: Supporting Oncologists in Capturing and Using Structured Oncology Data in Real-Time Using the Electronic Health Record (EHR)
Tevaarwerk, Amye J., Gatten, Clare A., Simret, Teshome, Carroll, Jamie M. , Advani, Pooja , Chumsri, Sarayana, Mandrekar, Sumithra J. , Giridhar, Karthik V. , Chumsri, Sarayana, Jin, Zhaohui

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 28, 2025 | Volume: 23 | Issue: 3.5 | Pages: No page available

10.6004/jnccn.2024.7350 Get It

CLO25-095: Baseline Genomic Alterations as Predictors of Response to Anti-HER2 Therapy in HER2-Amplified Advanced Colorectal Cancer (aCRC)
Hoyek, Celine , Pirozzi, Angelo , Zheng-Lin, Binbin , Lida, N., Ramaker, Ryne C. , Abidoye, Seyi, Wu, Christina, Ahn, Daniel H. , Rimassa, Lorenza, Rimassa, Lorenza , Rimassa, Lorenza , Eslinger, Cody , Shibuki, Taro , Sonbol, Mohamad Bassam , Borad, Mitesh J. , Ikeda, Masafumi , Nakamura, Yoshiaki , Yoshino, Takayuki , Strickler, John H. , Bekaii‐Saab, Tanios

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 28, 2025 | Volume: 23 | Issue: 3.5 | Pages: No page available

10.6004/jnccn.2024.7161 Get It

BIO25-027: Addressing Early Diagnosis Challenges: Utilizing C the Signs Clinical Decision Support Platform for Pancreatic Cancer Risk Assessment
Raoof, Sana , Dadhania, Seema , Herrick, Brian, Bakshi, Bea, Payling, Miles, Patel, Tushar

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 28, 2025 | Volume: 23 | Issue: 3.5 | Pages: No page available

10.6004/jnccn.2024.7196 Get It

Cyst Detection Ratio, a Quality Indicator for EUS-Based Pancreatic Cancer Screening: A Systematic Review and Meta-Analysis to inform Quality Improvement Benchmark
Chhoda, Ankit , Grimshaw, Andrew, Sawhney, Mandeep , Woodbine, Maria Jose Hernandez , Magahis, Patrick T. , Manoj, Matthew Antony , Grimshaw, A

Mayo Clinic

Endoscopy | March 27, 2025 | Volume: 57 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1806286 Get It

Capnocytophaga canimorsus from Dog Saliva Exposure Causing Severe Sepsis in a Healthy Adult: A Case Report
Stephens, Megan A., Silin, Nawras , Dakkak, Tahani , Sathian, Sangamithra, Singh, Hardeep , Bongu, Navneeth, Ghosh, Aditya K , Singh, Hardeep , Stephens, Megan A., Ghosh, Aditya

Mayo Clinic

American Journal of Case Reports | March 26, 2025 | Volume: 26 | Issue: No issue available | Pages: No page available

10.12659/ajcr.946691 | PMID 40279321 Get It

Therapeutic Targets in Glioblastoma: Molecular Pathways, Emerging Strategies, and Future Directions
Tang, Justin , Karbhari, Nishika , Campian, Jian , Karbhari, Nishika

Mayo Clinic

Cells | March 26, 2025 | Volume: 14 | Issue: 7 | Pages: 494

10.3390/cells14070494 | PMID 40214448 Get It

Glioblastoma (GBM) is the most aggressive primary brain tumor in adults, characterized by rapid growth, invasive infiltration into surrounding brain tissue, and resistance to conventional therapies. Despite advancements in surgery, radiotherapy, and chemotherapy, median survival remains approximately 15 months, underscoring the urgent need for innovative treatments. Key considerations informing treatment development include oncogenic genetic and epigenetic alterations that may dually serve as therapeutic targets and facilitate treatment resistance. Various immunotherapeutic strategies have been explored and continue to be refined for their anti-tumor potential. Technical aspects of drug delivery and blood–brain barrier (BBB) penetration have been addressed through novel vehicles and techniques including the incorporation of nanotechnology. Molecular profiling has emerged as an important tool to individualize treatment where applicable, and to identify patient populations with the most drug sensitivity. The goal of this review is to describe the spectrum of potential GBM therapeutic targets, and to provide an overview of key trial outcomes. Altogether, the progress of clinical and preclinical work must be critically evaluated in order to develop therapies for GBM with the strongest therapeutic efficacy.
2024 American College of Rheumatology ( ACR ) Guideline for the Screening, Treatment, and Management of Lupus Nephritis
Sammaritano, Lisa R. , Askanase, Anca , Bermas, Bonnie L. , Dall’Era, Maria , Duarte‐García, Alí , Hiraki, Linda T. , Rovin, Brad H. , Alvarado, Anthony, Aranow, Cynthia , Broder, Anna , Chowdhary, Vaidehi , Contreras, Gabriel, Felix, Christele, Gibson, Keisha L. , Hersh, Aimee O. , Kalunian, Kenneth , Rollins, Brandi , Smith, Benjamin J. , Thomas, Asha , Timlin, Homa , Ward, Michael D. , Bartels, Christie M. , Cunha, Joanne S., DeQuattro, Kimberly , Figueroa‐Parra, Gabriel , Greco, Jessica , Iyer, Priyanka , Johannemann, Andrew, Jorge, April , Kasturi, S.Psi. Taufik , Khawandi, Jana , Legge, Alexandra , Liang, Kelly V. , Lockwood, Megan M. , Sánchez-Rodríguez, Alain , Turgunbaev, Marat, Williams, Jessica N. , Turner, Amy S. , Aranow, Cynthia , Barnado, April , Brunner, Hermine I , Ferucci, Elizabeth D , Hersh, Aimee O , Smith, Benjamin J , Wallace, Daniel J , Bartels, Christie M , DeQuattro, Kimberly , Figueroa-Parra, Gabriel , Garg, Shivani , Cuéllar-Gutiérrez, María C, Jorge, April , Kasturi, Shanthini , Kawtharany, Hassan , Kirou, Kyriakos A , Lockwood, Megan M , Sanchez-Rodriguez, Alain , Williams, Jessica N , Turner, Amy S , Duarte-García, Alí , Rovin, Brad H , Askanase, Anca , Bermas, Bonnie , Son, Mary Beth F. , Barnado, April , Contreras, Gabriel, Ferucci, Elizabeth D. , Izmirly, Peter , Kamen, Diane L. , Rollins, Brandi, Thomas, Asha, Azzam, Muayad , Fava, Andrea , Garg, Shivani , Cuéllar‐Gutiérrez, María C. , Kawtharany, Hassan , Kirou, Kyriakos A. , Mustafa, Reem A

Mayo Clinic

Arthritis Care & Research | March 26, 2025 | Volume: 77 | Issue: 9 | Pages: 1045-1065

10.1002/acr.25528 | PMID 40127995 Get It

Objective The objective is to provide evidence‐based and expert guidance for the screening, treatment, and management of lupus nephritis. Methods The Core Team developed clinical questions for screening, treatment, and management of lupus nephritis using the PICO format (population, intervention, comparator, and outcome). Systematic literature reviews were completed for each PICO question, and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology was used to assess the quality of evidence and to formulate recommendations. The Voting Panel achieved a consensus ≥70% on the direction (for or against) and strength (strong or conditional) of each recommendation. Results We present 28 graded recommendations (7 strong, 21 conditional) and 13 ungraded, consensus‐based good practice statements for the screening and management of lupus nephritis. Our recommendations focus on the unifying principle that lupus nephritis therapy is continuous and ongoing, rather than consisting of discrete induction/initial and maintenance/subsequent therapies. Therapy should include pulse glucocorticoids followed by oral glucocorticoid taper and two additional immunosuppressive agents for 3–5 years for those achieving complete renal response. Conclusion This guideline provides direction for clinicians regarding screening and treatment decisions for management of lupus nephritis. These recommendations should not be used to limit or deny access to therapies, as treatment decisions may vary due to the unique clinical situation and personal preferences of each individual patient.